Max Rosett - Sep 19, 2024 Form 4 Insider Report for Immunome Inc. (IMNM)

Role
Chief Financial Officer
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Stock symbol
IMNM
Transactions as of
Sep 19, 2024
Transactions value $
-$186,124
Form type
4
Date filed
9/20/2024, 07:26 PM
Previous filing
Aug 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMNM Common Stock Options Exercise $44.1K +42K +211.52% $1.05 61.9K Sep 19, 2024 Direct
transaction IMNM Common Stock Sale -$230K -14.4K -23.25% $16.01 47.5K Sep 19, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNM Stock option (right to buy) Options Exercise $0 -42K -31.38% $0.00 91.8K Sep 19, 2024 Common Stock 42K $1.05 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to sell to cover transactions.
F2 The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F3 The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05.
F4 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.